{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:27Z","timestamp":1789556607182,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008272","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T00:00:00Z","timestamp":1268784000000}}],"reference-count":33,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008272.pub2","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T07:46:30Z","timestamp":1268725590000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults"],"prefix":"10.1002","volume":"2011","author":[{"given":"Nandi","family":"Siegfried","sequence":"first","affiliation":[{"name":"University of Cape Town; Department of Public Health and Primary Health Care; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan A","family":"Uthman","sequence":"additional","affiliation":[{"name":"University of Birmingham; WMHTAC, Public Health, Epidemiology & Biostatistics; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Global Health Sciences; 50 Beale Street Suite 1200 San Francisco California USA 94105"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,17]]},"reference":[{"key":"10.1002\/14651858.CD008272.pub2-BIB0001|cit1","unstructured":"Fitzgerald D A randomized clinical trial of early versus strandard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200 - 350 cells\/ml (CIPRA HT 001) International AIDS Society Conference, Cape Town 2009"},{"issue":"22","key":"10.1002\/14651858.CD008272.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"8","key":"10.1002\/14651858.CD008272.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1086\/529523","article-title":"Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up","volume":"197","author":"Lundgren","year":"2008","journal-title":"The Journal of infectious diseases"},{"issue":"15 April","key":"10.1002\/14651858.CD008272.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"The Strategies for Management of Antiretroviral Therapy (SMART) Study Group","year":"2008","journal-title":"The Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008272.pub2-BIB0005|cit5","first-page":"153","article-title":"HAART \u2013 Dependent CD4+ Lymphocyte Response Based onPre-Therapeutic CD4 Lymphocyte Count in HIV-Infected Nigerians","volume":"5","author":"Erhabor","year":"2006","journal-title":"Annals of African Medicine"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0006|cit6","unstructured":"Early initiation of HAART Ongoing study October 2007"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0007|cit7","unstructured":"Strategic Timing of Antiretroviral Treatment (START) Ongoing study March 2009"},{"issue":"8","key":"10.1002\/14651858.CD008272.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/00002030-200405210-00009","article-title":"Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines","volume":"18","author":"Badri","year":"2004","journal-title":"AIDS (London, England)"},{"issue":"3","key":"10.1002\/14651858.CD008272.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-148-3-200802050-00004","article-title":"Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model","volume":"148","author":"Braithwaite","year":"2008","journal-title":"Annals of internal medicine"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0010|cit10","article-title":"Table for grading the severity of Adult and Pediatric Adverse Events","author":"Division of","year":"http:\/\/rcc.tech-res.com\/Document\/safetyandpharmacovigilance\/DAIDS_AE_GradingTable_Clarification_August2009_Final.pdf","journal-title":"Accessed 28 October 2009"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0011|cit11","article-title":"Clinical and operational guidelines for use of antiretroviral therapy in adults","author":"Day","year":"2002","journal-title":"Aurum Health Research"},{"issue":"7556","key":"10.1002\/14651858.CD008272.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/bmj.332.7556.1489","article-title":"Antiretroviral treatment of HIV infected adults","volume":"332","author":"Deeks","year":"2006","journal-title":"BMJ (Clinical research ed.)"},{"issue":"3","key":"10.1002\/14651858.CD008272.pub2-BIB0013|cit13","first-page":"153","article-title":"HAART - Dependent CD4+ Lymphocyte Response Based on Pre-Therapeutic CD4 Lymphocyte Count in HIV-Infected Nigerians","volume":"5","author":"Erhabor","year":"2006","journal-title":"Annals of African Medicine"},{"issue":"9657","key":"10.1002\/14651858.CD008272.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0140-6736(08)61697-9","article-title":"Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model","volume":"373","author":"Granich","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008272.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD008272.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0017|cit17","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","author":"Higgens","year":"2008"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/biomet\/74.1.149","article-title":"Design and analysis of group sequential tests based on the type 1 error spending rate function","volume":"74","author":"Kim","year":"1987","journal-title":"Biometrika"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0019|cit19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival","author":"Kitahata","year":"2009","journal-title":"The New England journal of medicine"},{"issue":"2","key":"10.1002\/14651858.CD008272.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/135965350801300209","article-title":"When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience","volume":"13","author":"Loubiere","year":"2008","journal-title":"Antiviral therapy"},{"issue":"18","key":"10.1002\/14651858.CD008272.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1097\/QAD.0b013e3282f09876","article-title":"Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa","volume":"21","author":"Moh","year":"2007","journal-title":"AIDS (London, England)"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0023|cit23","doi-asserted-by":"crossref","DOI":"10.1177\/135965350701200106","article-title":"Conservation of first-line antiretroviral treatmentregimen where therapeutic options are limited","volume":"12","author":"Orrell","year":"2007","journal-title":"Antiviral Therapy"},{"issue":"8","key":"10.1002\/14651858.CD008272.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1002\/14651858.CD008272.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/QCO.0b013e328326cd34","article-title":"Should HIV therapy be started at a CD4 cell count above 350 cells\/microl in asymptomatic HIV-1-infected patients?","volume":"22","author":"Sabin","year":"2009","journal-title":"Current opinion in infectious diseases"},{"issue":"21","key":"10.1002\/14651858.CD008272.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/archinte.162.21.2478","article-title":"Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults","volume":"162","author":"Schackman","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-6405-5-21","article-title":"Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir\/ritonavir tablet formulation compared with soft gel capsules","volume":"5","author":"Schrader","year":"2008","journal-title":"AIDS research and therapy"},{"issue":"17","key":"10.1002\/14651858.CD008272.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00002030-200111230-00006","article-title":"HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy","volume":"15","author":"Sterling","year":"2001","journal-title":"AIDS (London, England)"},{"issue":"9672","key":"10.1002\/14651858.CD008272.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies","volume":"373","author":"Sterne","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008272.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-151-3-200908040-00138","article-title":"When to start antiretroviral therapy in resource-limited settings","volume":"151","author":"Walensky","year":"2009","journal-title":"Annals of internal medicine"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0031|cit31","article-title":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2006 revision","author":"Charles","year":"(accessed July 2007)","journal-title":"http:\/\/www.who.int\/hiv\/pub\/guidelines\/adult\/en\/index.html"},{"key":"10.1002\/14651858.CD008272.pub2-BIB0032|cit32","article-title":"Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents","author":"World Health Organization","year":"November 2009","journal-title":"Geneva: World Health Organization"},{"issue":"2","key":"10.1002\/14651858.CD008272.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/apc.2006.0037","article-title":"Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong","volume":"21","author":"Wong","year":"2007","journal-title":"AIDS patient care and STDs"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008272.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:17:42Z","timestamp":1789553862000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008272.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane HIV\/AIDS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,3,17]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008272.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,17]]}}}